Leading the Way in Intranasal Vaccines
Next
Aptar Pharma can help you start your new nasal vaccine project by offering a Starter Kit for Intranasal drug delivery.
The kit can also help with antiviral, antibody and immunotherapy projects to help accelerate your new drug development project.
The advantages of this kit are:
What’s in the kit?
Aptar Pharma’s nasal vaccine systems are ready to meet the needs of the vaccine industry. Our nasal vaccine devices can be filled on a wide range of existing production lines at CMOs or in-house manufacturing facilities or ready to use at the HCP. Production can be quickly scaled up to meet virtually any demand. From early clinical to global commercial scale, nasal vaccines are highly manufacturable. Nasal vaccines can also be cost-effective when compared to traditional sterile injectable vaccines, considering the complexity of multi-component sterile manufacturing.
Some nasal vaccines, including powder vaccines can avoid cold-chain requirement making their transportation to anywhere in the world easier. Offering intranasal vaccines to Health Care Professionals (HCPs) in addition to your existing oral and injectable vaccination offering, enhances your brand differentiation. All these advantages, combined with Aptar Pharma’s proven regulatory success including a U.S. FDA approved market reference, means our nasal vaccine systems are proven market ready for today’s vaccine requirements.
Development of an effective intranasal vaccine has numerous potential advantages over conventional, subcutaneous or intramuscular-based delivery. First, the nasal passageway is very often the first point of entry for certain pathogens; if the pathogen can be halted in the nasal passages, curtailing the spread of infection further, this could lead to an improved overall prognosis. In addition, the direct immunization of nasal mucosa may promote systemic and mucosal immunity, which may help prevent viral shedding and disease transmission.
Furthermore, self-administration of a nasal powder vaccine provides for “needle free” administration to the patient avoids the need for syringe disposal, and potentially simplifies global distribution with the elimination of extreme cold from the supply chain. These aspects of nasal delivery could open up vaccine availability to larger populations in regions and countries with limited refrigeration infrastructure.
Aptar Pharma’s nasal vaccine systems may be pre-filled to avoid complex or risky on-site preparation steps required for some lyophilized or multicomponent injection systems. Overall, Aptar Pharma’s range of nasal vaccine devices provide an efficient, patient centric solution in both clinical and commercial settings for vaccine administration.
With both powder and liquid nasal vaccine formulation options, Aptar Pharma’s nasal vaccine devices are suitable for a wide range of vaccine types. Nasal sprays present a strong alternative approach for both therapeutic and prophylactic nasal vaccine approaches. Therapeutic treatments of cancer, autoimmune and infectious diseases as well as prophylactic treatments vaccines for Covid-19 have been studied and developed in nasal vaccine formats.
These formulations can incorporate a range of vaccine types including DNA/RNA, live attenuated, inactivated, subunit and viral vectors. Nasal vaccine formulations may contain antigens, adjuvants and a range of available excipients in order to deliver the vaccine to patients intranasally. With such a wide range of possible vaccine types and formulation approaches that are suitable for Aptar Pharma nasal vaccine devices, the number and patient acceptance of nasal vaccines will continue to grow rapidly.
Aptar Pharma nasal vaccine systems can offer a range of feature driven benefits, not found with traditional injectable vaccines. Our nasal vaccine devices can handle liquid, powder and reconstituted formulations and offers variable dose volume options through its advanced designs. Sterile device components can provide dosing flexibility and maintain the sterility of the product formulation.
Powder nasal vaccine formulations can utilize minimal formulation, that use very few excipients and exclude moisture, enabling enhanced product stability and extended shelf life. Powder vaccines can also enable high payload delivery when required. The ability to avoid cold chain storage requirements for many powder nasal vaccines, makes global distribution of critical vaccines possible even to remote or undeveloped regions.
With a proven track record as a leader in nasal drug delivery combined with its specialized knowledge of nasal vaccine science, Aptar Pharma is an ideal partner to develop your next nasal vaccine product. Offering advanced nasal vaccine device designs across its range, Aptar Pharma also provides specialized support services to make the development process easy for its customers.
From device selection, formulation/analytical development and regulatory support Aptar Pharma works with you every step of the way. With sophisticated in-vitro modelling and analytical testing, we offer specialized nasal vaccine knowledge and capabilities that you won’t find elsewhere. Our technologies have been utilized in many customer products and combination products that have successfully been approved by leading regulatory bodies including the U.S. FDA and EMA. With numerous market references, Aptar Pharma has the proven regulatory track record to give you confidence in our comprehensive regulatory support services. We take you from formulation to patient.
We offer various customizable container size options.
Liquid dose ranges: 100 and 250mL
Powder dose: 10 to 80 mg
Aptar Pharma can help bring new life to established vaccines through our customized vaccine repositioning and lifecycle management services. We can help to differentiate and reformulate your existing product to extend its life and provide valuable differentiation in the marketplace.
For more information on Vaccine Repositioning and Lifecycle Management services click here or check out our Knowledge Hub for more background.
Speak to an Aptar Pharma expert today to find out more about how we can rejuvenate your vaccine product.
Aptar Pharma works closely with its customers in the spirit of partnership. Whether you need beginning to end development and manufacturing support or just want to source industry-leading device technologies, Aptar Pharma can support your needs. In addition to our comprehensive in-house services, we also work with a broad network of service partners, including CDMOs and CMOs, helping us to deliver complete global services from small scale clinical manufacturing to large scale commercial volumes.
Start you intranasal vaccine project with a world leader in nasal drug delivery.